Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PRGO

These 3 Dividend Stocks Combine Strong Yields With Upside

These three high-yield dividend stocks are well-positioned to deliver a strong return, making them attractive to both income and growth-oriented investors

MarketBeat

3 Dividend Stocks to Buy Now With Yields of About 4% or More

Three dividend stocks, Kimco Realty, Perrigo Company, and Permian Resources, are highlighted as attractive options for investors seeking steady income, with yields of 3.9% or more and strong fundamentals across the real estate, healthcare, and energy sectors.

Barchart

3 Lucrative Pharma Stocks to Diversify Your Investments

The pharma industry’s resilience and long-term prospects are driven by rising healthcare demand, an enhanced focus on precision medicines, and technological advancements. Hence, let’s take a look at pharma stocks Perrigo Company (PRGO), Amneal Pharmaceuticals (AMRX), and Supernus Pharmaceuticals (SUPN), which could diversify your investments. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Stocks to Consider for March Gains

The pharmaceutical industry is experiencing rapid growth due to rising healthcare spending, an aging population, several technological advancements, and a favorable regulatory environment. Thus, it could be ideal to invest in quality pharma stocks Perrigo (PRGO), OptiNose (OPTN), and Teva Pharmaceutical (TEVA) for solid gains. Keep reading….

StockNews.com

Bolster Your Portfolio with These 3 Pharma Stock Buys

The pharmaceutical industry is booming because of the increasing need for quality healthcare and high-quality medicines, the fast-growing elderly population, and the uptick in chronic illnesses. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Perrigo Company (PRGO), ACADIA Pharmaceuticals (ACAD), and Pacira BioSciences…

StockNews.com

Relay Therapeutics (RLAY) vs. Perrigo Company (PRGO): Which Pharma Stock Holds Better Upside Potential?

The pharmaceutical industry’s prospects look bright, fueled by a rapidly aging population, the rising prevalence of chronic diseases, consistent R&D efforts backed by government funding, and digital transformation. Pharma stocks Relay Therapeutics (RLAY) and Perrigo Company (PRGO) should benefit from the industry tailwinds. But let’s find out which stock holds…

StockNews.com

Is Perrigo a Buy After Reporting Q1 Earnings?

The shares of leading baby formula maker Perrigo Company (PRGO) have been soaring in price of late amid a nationwide baby formula shortage. So, because the crisis is expected to continue through the coming months, will PRGO be able to maintain this momentum in the near term? Read more to…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Perrigo Shares Pop On Raised FY22 Guidance Surpassing Consensus Estimates

Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion. The growth was led by strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. after competitor recall. Adjusted EPS decreased 34% to $0.33, as higher sales…

Benzinga

Perrigo Clocks 5% Sales Growth In Q4, Bottom-Line Surpass Expectation

Perrigo Company plc (NYSE: PRGO)

Benzinga

Perrigo: Q4 Earnings Insights

Perrigo (NYSE:PRGO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

People

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

ACADIA Pharmaceuticals Inc

15 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.